Invasive candidiasis is a prevalent and life-threatening fungal infection. Various Candida spp. can cause invasive candidiasis and immunocompromised individuals are at a higher risk of infection. The four main classes of antifungals used to treat fungal infections caused by Candida species are polyenes, pyrimidine analogues, azoles, and echinocandins. An increase in the number of azole- and echinocandin-resistant Candida isolates and the emergence of the multi-drug resistant Candida auris threaten the efficacy of current treatment regimes. A novel drug manogepix which is the active moiety of the prodrug fosmanogepix currently in phase 2 clinical trial, is the focus of multiple research studies to establish the efficacy relative to the current treatment protocols adopted in the clinical setting. The aim of the proposed project is to investigate how manogepix would affect the viability of the different Candida spp. Through our findings, we also aim to establish possible synergistic and antagonistic effects with other antifungals using a checkerboard assay. The effect on the growth and viability of the Candida strains will be recorded using live-cell imaging and an automated microscope. We hope that the conclusions drawn from the project would help to pave the way for developing new treatment strategies.